Article Details

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Buy" by Brokerages

Retrieved on: 2020-11-23 14:48:45

Tags for this article:

Click the tags to see associated articles and topics

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Buy" by Brokerages. View article details on hiswai:

Excerpt

<b>Vanguard Group</b> Inc. now owns 7,117,697 shares of the biotechnology company's stock valued at $1,141,251,000 after buying an additional 572,908 ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo